HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
Provided By GlobeNewswire
Last update: May 13, 2025
Addresses key challenges for CAR-T therapies
Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells
Read more at globenewswire.comNASDAQ:HCWB (8/18/2025, 3:21:01 PM)
4.0172
-0.07 (-1.78%)
Find more stocks in the Stock Screener
